O	0	10	Randomized
O	11	16	phase
O	17	19	II
O	20	25	study
O	26	28	of
B-intervention	29	32	nab
I-intervention	32	33	-
I-intervention	33	43	paclitaxel
O	44	46	as
O	47	52	first
O	52	53	-
O	53	57	line
O	58	70	chemotherapy
O	71	73	in
O	74	82	patients
O	83	87	with
O	88	92	HER2
O	92	93	-
O	93	101	negative
O	102	112	metastatic
O	113	119	breast
O	120	126	cancer
O	126	127	.

O	128	134	Weekly
O	135	149	administration
O	150	152	of
O	153	165	nanoparticle
O	166	173	albumin
O	173	174	-
O	174	179	bound
O	180	190	paclitaxel
O	191	192	(
O	192	195	nab
O	195	196	-
O	196	206	paclitaxel
O	206	207	)
O	208	211	has
O	212	216	been
O	217	222	shown
O	223	225	to
O	226	228	be
O	229	230	a
O	231	235	safe
O	236	239	and
O	240	249	effective
O	250	259	treatment
O	260	263	for
O	264	274	metastatic
O	275	281	breast
O	282	288	cancer
O	289	290	(
O	290	293	MBC
O	293	294	)
O	295	297	in
O	298	306	clinical
O	307	314	studies
O	314	315	.

O	316	318	We
O	319	328	conducted
O	329	330	a
O	331	342	multicenter
O	342	343	,
O	344	354	randomized
O	354	355	,
O	356	360	open
O	360	361	-
O	361	366	label
O	367	372	phase
O	373	375	II
O	376	381	study
O	382	384	to
O	385	392	compare
O	393	396	the
O	397	405	efficacy
O	406	409	and
O	410	416	safety
O	417	419	of
O	420	426	weekly
O	427	430	nab
O	430	431	-
O	431	441	paclitaxel
O	442	445	and
O	446	455	docetaxel
O	456	458	in
B-ethinicity	459	467	Japanese
B-eligibility	468	476	patients
I-eligibility	477	481	with
I-eligibility	482	487	human
I-eligibility	488	497	epidermal
I-eligibility	498	504	growth
I-eligibility	505	511	factor
I-eligibility	512	520	receptor
I-eligibility	521	522	2
I-eligibility	522	523	-
I-eligibility	523	531	negative
I-eligibility	532	535	MBC
O	535	536	.

O	537	540	The
O	541	548	primary
O	549	557	endpoint
O	558	561	was
B-outcome-Measure	562	573	progression
I-outcome-Measure	573	574	-
I-outcome-Measure	574	578	free
I-outcome-Measure	579	587	survival
I-outcome-Measure	588	589	(
I-outcome-Measure	589	592	PFS
I-outcome-Measure	592	593	)
O	593	594	.

O	595	603	Patients
O	604	608	were
O	609	619	randomized
O	620	622	to
O	623	630	receive
O	631	634	nab
O	634	635	-
O	635	645	paclitaxel
O	646	647	(
O	647	650	150
O	651	653	mg
O	653	654	/
O	654	656	m2
O	657	660	nab
O	660	661	-
O	661	671	paclitaxel
O	672	676	once
O	677	680	per
O	681	685	week
O	686	689	for
O	690	691	3
O	692	694	of
O	695	696	4
O	697	702	weeks
O	702	703	;
O	704	705	n
O	706	707	=
B-intervention-participants	708	711	100
O	711	712	)
O	713	715	or
B-control	716	725	docetaxel
O	726	727	(
O	727	729	75
O	730	732	mg
O	732	733	/
O	733	735	m2
O	736	745	docetaxel
O	746	751	every
O	752	753	3
O	754	759	weeks
O	759	760	;
O	761	762	n
O	763	764	=
B-control-participants	765	768	100
O	768	769	)
O	769	770	.

O	771	774	The
B-outcome	775	781	median
I-outcome	782	785	PFS
O	786	788	by
O	789	800	independent
O	801	812	radiologist
O	813	823	assessment
O	824	827	was
B-iv-cont-median	828	829	9
I-iv-cont-median	829	830	.
I-iv-cont-median	830	831	8
I-iv-cont-median	832	838	months
O	839	840	(
O	840	842	90
O	842	843	%
O	844	854	confidence
O	855	863	interval
O	864	865	[
O	865	867	CI
O	867	868	]
O	868	869	:
O	870	871	8
O	871	872	.
O	872	873	5
O	873	874	-
O	874	876	11
O	876	877	.
O	877	878	2
O	878	879	)
O	880	883	for
O	884	887	nab
O	887	888	-
O	888	898	paclitaxel
O	899	902	and
B-cv-cont-median	903	905	11
I-cv-cont-median	905	906	.
I-cv-cont-median	906	907	2
I-cv-cont-median	908	914	months
O	915	916	(
O	916	918	90
O	918	919	%
O	920	922	CI
O	922	923	:
O	924	925	8
O	925	926	.
O	926	927	4
O	927	928	-
O	928	930	13
O	930	931	.
O	931	932	8
O	932	933	)
O	934	937	for
O	938	947	docetaxel
O	948	949	(
O	949	955	hazard
O	956	961	ratio
O	961	962	:
O	963	964	1
O	964	965	.
O	965	967	25
O	967	968	,
O	969	970	P
O	971	972	=
O	973	974	0
O	974	975	.
O	975	978	363
O	978	979	)
O	979	980	,
O	981	984	and
O	985	988	the
B-outcome	989	995	median
I-outcome	996	1003	overall
I-outcome	1004	1012	survival
O	1013	1016	was
B-iv-cont-median	1017	1019	42
I-iv-cont-median	1019	1020	.
I-iv-cont-median	1020	1021	4
I-iv-cont-median	1022	1028	months
O	1029	1032	and
B-cv-cont-median	1033	1035	34
I-cv-cont-median	1035	1036	.
I-cv-cont-median	1036	1037	0
I-cv-cont-median	1038	1044	months
O	1044	1045	,
O	1046	1058	respectively
O	1058	1059	.

O	1060	1063	The
B-outcome	1064	1071	overall
I-outcome	1072	1080	response
I-outcome	1081	1085	rate
O	1086	1089	was
B-iv-bin-percent	1090	1092	56
I-iv-bin-percent	1092	1093	.
I-iv-bin-percent	1093	1094	1
I-iv-bin-percent	1094	1095	%
O	1096	1099	for
O	1100	1103	nab
O	1103	1104	-
O	1104	1114	paclitaxel
O	1115	1118	and
B-cv-bin-percent	1119	1121	52
I-cv-bin-percent	1121	1122	.
I-cv-bin-percent	1122	1123	5
I-cv-bin-percent	1123	1124	%
O	1125	1128	for
O	1129	1138	docetaxel
O	1138	1139	.

O	1140	1147	Adverse
O	1148	1154	events
O	1155	1157	in
O	1158	1162	both
O	1163	1172	treatment
O	1173	1177	arms
O	1178	1182	were
O	1183	1190	similar
O	1191	1193	to
O	1194	1202	previous
O	1203	1210	reports
O	1210	1211	.

B-outcome	1212	1223	Neutropenia
O	1224	1227	was
O	1228	1231	the
O	1232	1236	most
O	1237	1243	common
O	1244	1251	adverse
O	1252	1257	event
O	1258	1260	in
O	1261	1265	both
O	1266	1270	arms
O	1270	1271	,
O	1272	1276	with
B-iv-bin-percent	1277	1279	35
I-iv-bin-percent	1279	1280	.
I-iv-bin-percent	1280	1281	0
I-iv-bin-percent	1281	1282	%
O	1283	1285	of
O	1286	1294	patients
O	1295	1297	in
O	1298	1301	the
O	1302	1305	nab
O	1305	1306	-
O	1306	1316	paclitaxel
O	1317	1320	arm
O	1321	1324	and
B-cv-bin-percent	1325	1327	89
I-cv-bin-percent	1327	1328	.
I-cv-bin-percent	1328	1329	0
I-cv-bin-percent	1329	1330	%
O	1331	1333	in
O	1334	1337	the
O	1338	1347	docetaxel
O	1348	1351	arm
O	1352	1364	experiencing
B-outcome	1365	1370	grade
I-outcome	1371	1372	4
I-outcome	1373	1384	neutropenia
O	1384	1385	.

B-outcome	1386	1391	Grade
I-outcome	1392	1393	3
I-outcome	1394	1404	peripheral
I-outcome	1405	1412	sensory
I-outcome	1413	1423	neuropathy
O	1424	1432	occurred
O	1433	1435	in
B-iv-bin-percent	1436	1438	22
I-iv-bin-percent	1438	1439	.
I-iv-bin-percent	1439	1440	0
I-iv-bin-percent	1440	1441	%
O	1442	1444	of
O	1445	1453	patients
O	1454	1456	in
O	1457	1460	the
O	1461	1464	nab
O	1464	1465	-
O	1465	1475	paclitaxel
O	1476	1479	and
B-cv-bin-percent	1480	1481	5
I-cv-bin-percent	1481	1482	.
I-cv-bin-percent	1482	1483	0
I-cv-bin-percent	1483	1484	%
O	1485	1487	in
O	1488	1491	the
O	1492	1501	docetaxel
O	1502	1505	arm
O	1505	1506	.

O	1507	1509	In
O	1510	1514	this
O	1515	1520	study
O	1520	1521	,
O	1522	1530	although
O	1531	1537	weekly
O	1538	1541	nab
O	1541	1542	-
O	1542	1552	paclitaxel
O	1553	1556	150
O	1557	1559	mg
O	1559	1560	/
O	1560	1562	m2
O	1563	1566	did
O	1567	1570	not
O	1571	1575	show
O	1576	1587	superiority
O	1588	1590	in
O	1591	1594	PFS
O	1595	1603	compared
O	1604	1608	with
O	1609	1618	docetaxel
O	1618	1619	,
O	1620	1628	efficacy
O	1629	1637	outcomes
O	1638	1642	were
O	1643	1650	similar
O	1651	1653	in
O	1654	1662	patients
O	1663	1670	treated
O	1671	1675	with
O	1676	1682	weekly
O	1683	1686	nab
O	1686	1687	-
O	1687	1697	paclitaxel
O	1698	1701	and
O	1702	1711	docetaxel
O	1711	1712	.
